5.49
-0.18
(-3.17%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 5.45 - 5.90 |
| 52 week | 3.00 - 8.25 |
| Open | 5.70 |
| Vol / Avg. | 372,210.00/595,396.00 |
| Mkt cap | 222.31M |
| P/E | - |
| Div/yield | - |
| EPS | -1.71 |
| Shares | 40.49M |
| Beta | - |
| Inst. own | 81% |
Events
May 9, 2013
Q1 2013 Anacor Pharmaceuticals Inc Earnings Conference Call
Mar 21, 2013
Anacor Pharmaceuticals Inc Corporate Conference Call to Discuss Preliminary Results From the Phase 2 Dose-Ranging Study of AN2728 in the Treatment of Adolescents With Atopic Dermatitis
Mar 14, 2013
Q4 2012 Anacor Pharmaceuticals Inc Earnings Conference Call
Mar 4, 2013
Anacor Pharmaceuticals Inc at Cowen Health Care Conference
Feb 28, 2013
Anacor Pharmaceuticals Inc to Discuss Positive Results from the Second Phase 3 Trial of Tavaborole for Onychomycosis Conference Call
Feb 25, 2013
Anacor Pharmaceuticals Inc at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -882.79% | -522.23% |
| Operating margin | -829.45% | -495.27% |
| EBITD margin | - | -489.06% |
| Return on average assets | -136.75% | -104.97% |
| Return on average equity | - | -599.54% |
| Employees | 85 | - |
| Carbon Disclosure Rating | - | - |
Address
1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has discovered, synthesized and developed seven molecules that are in development. Its lead product candidates include two topically administered dermatologic compounds tavaborole and AN2728. In addition, the Company has discovered three compounds that it has out-licensed for further developmentGSK2251052 (GSK '052), AN8194 and AN5568. The Company's clinical pipeline also includes two additional product candidates. AN2718, its second topical antifungal product candidate, has the potential to treat onychomycosis and fungal infections of the skin. AN2898, the Company's second topical anti-inflammatory product candidate, has the potential to treat atopic dermatitis and psoriasis.
Officers and directors
| Mark Leschly MBA | Independent Chairman of the Board | |
| David P Perry MBA | President, Chief Executive Officer, Director | |
| Geoffrey M. Parker MBA | Chief Financial Officer, Senior Vice President | |
| Irwin A Heyman PhD | Senior Vice President - Drug Development | |
| Kirk R Maples Ph.D. | Senior Vice President - Program Management | |
| Jacob J Plattner Ph.D. | Senior Vice President - Research | |
| Paul L Berns | Director | |
| Anders D. Hove M.D. | Independent Director | |
| Paul H. Klingenstein MBA | Independent Director | |
| William J. Rieflin | Independent Director |